1. Smahel, M., Sobotková, E., Bubeník, J., Símová, J., 2ák, R., Ludvíková, V., Hájková, R., Kovarik, J., Jelínek, F., Povÿsil, C., Marinov, J. and Vonka, V., in press, Metastatic MHC class I negative mouse cells derived by transformation with human papillomaviruses type 16: A model for studies on vaccination against papillomavirus-associated tumours..Brit. J. Cancer.
2. Bubeník, J, Símová, J., Hájková, R., Sobota, V., Jandlová T, Smahel, M., Sobotková, E., Vonka, V., 1999, Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.Int J Oncol14: 593–597.
3. Shen, Z., Reznikoff, G., Dranoff, G., Rock, K.L., 1997, Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.J. Immunol.158: 2723–2730.
4. Mendoza, L., Indrová, M., Hájková, R., Reinis, M., Smahel, M., Vonka, V., Bubeník, J., Jandlová, T., 2000, Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth.Folia Biol (Praha)46: 91–97.
5. Indrová, M.., Bubenik, J., Símová, J., Vonka, V., N¨¨mei ková, S., Mendoza, L., Reinil, M., 2001, Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines:In vitropriming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.Int. J.Molec. Med.7: 97–100.